Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma. The company also develops enfortumab vedotin, which is in Phase 1 clinical trial for Nectin-4-positive solid tumors, including bladder cancer; and tisotumab vedotin that is in Phase II clinical trial for patients with cervical cancer and solid tumors. In addition, it conducts phase 3 clinical trials of ADCETRIS which includes ECHELON-1 for patients with newly diagnosed advanced stage classical Hodgkin lymphoma; ECHELON-2 for patients with newly diagnosed CD30-expressing MTCL; and the CHECKMATE 812 for patients with relapsed or refractory or transplant-ineligible, and advanced classical Hodgkin lymphoma. Further, the company's earlier stage clinical pipeline includes six other ADC programs consisting of ladiratuzumab vedotin, denintuzumab mafodotin, SGN-CD19B, SGN-CD123A, SGN-CD33A, and SGN-CD352A, as well as two immuno-oncology agents, including SEA-CD40 and SGN-2FF. It has collaborations for its ADC technology with various biotechnology and pharmaceutical companies, including AbbVie Biotechnology Ltd.; Bayer Pharma AG; Celldex Therapeutics, Inc.; Genentech, Inc.; GlaxoSmithKline LLC; Pfizer, Inc., PSMA Development Company LLC; Takeda Pharmaceutical Company Limited, Unum Therapeutics, Inc., and Genmab A/S, as well as has co-development agreement with Agensys, Inc. Seattle Genetics, Inc. was founded in 1998 and is headquartered in Bothell, Washington.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:SGEN
Previous Symbol
CUSIP81257810
Phone425-527-4000
Debt
Debt-to-Equity RatioN/A
Current Ratio3.70
Quick Ratio3.31
Price-To-Earnings
Trailing P/E Ratio-63.85
Forward P/E Ratio-38.75
P/E GrowthN/A
Sales & Book Value
Annual Sales$482.25 million
Price / Sales18.66
Cash FlowN/A
Price / CashN/A
Book Value$8.52 per share
Price / Book6.60
Profitability
EPS (Most Recent Fiscal Year)($0.88)
Net Income$-125,530,000.00
Net Margins-26.58%
Return on Equity-19.13%
Return on Assets-16.36%
Miscellaneous
Employees1,100
Outstanding Shares160,150,000
Market Cap$9.14 billion
OptionableOptionable
Seattle Genetics (NASDAQ:SGEN) Frequently Asked Questions
What is Seattle Genetics' stock symbol?
Seattle Genetics trades on the NASDAQ under the ticker symbol "SGEN."
How were Seattle Genetics' earnings last quarter?
Seattle Genetics, Inc. (NASDAQ:SGEN) issued its quarterly earnings data on Thursday, October, 25th. The biotechnology company reported ($0.42) EPS for the quarter, missing the Zacks' consensus estimate of ($0.27) by $0.15. The biotechnology company had revenue of $169.42 million for the quarter, compared to analyst estimates of $164.75 million. Seattle Genetics had a negative net margin of 26.58% and a negative return on equity of 19.13%. View Seattle Genetics' Earnings History.
When is Seattle Genetics' next earnings date?
What guidance has Seattle Genetics issued on next quarter's earnings?
Seattle Genetics updated its FY 2018 earnings guidance on Thursday, October, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $631-650 million, compared to the consensus revenue estimate of $659.86 million.
What price target have analysts set for SGEN?
15 analysts have issued 1-year price targets for Seattle Genetics' stock. Their forecasts range from $50.00 to $101.00. On average, they anticipate Seattle Genetics' share price to reach $77.5833 in the next year. This suggests a possible upside of 38.1% from the stock's current price. View Analyst Price Targets for Seattle Genetics.
What is the consensus analysts' recommendation for Seattle Genetics?
15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Seattle Genetics in the last year. There are currently 1 sell rating, 5 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Seattle Genetics.
What are Wall Street analysts saying about Seattle Genetics stock?
Here are some recent quotes from research analysts about Seattle Genetics stock:
- 1. Cann analysts commented, "We have anticipated impact for Adcetris in front-line PTCL starting in late 2019. The timing of the sBLA in this setting combined with positive top-line data for the ECHELON-2 study supports our outlook. Adcetris, Seattle Genetics’ approved drug for Hodgkin’s lymphoma, had sales of $307.6 million, or 63.8% of total revenue, in 2017. We estimate that Adcetris sales, including additional indications, PTCL and anaplastic large cell lymphoma, along with label expansion into front-line Hodgkin’s lymphoma earlier this year, will increase to $838.7 million in 2022 and account for 70.7% of revenue. Continued strong data from ECHELON-1 are expected to drive adoption in the front-line Hodgkin’s setting, and the positive top-line data for ECHELON-2 support our view for approval and adoption in front-line PTCL." (11/5/2018)
- 2. HC Wainwright analysts commented, "We reach a price target of $98 after adjusting new corporate tax rate, cash, and other program updates. The price target is based on a sum-of-parts NPV-DCF ($58.7 HL + $3.52 relapsed sALCL+ $11.8 frontline PTCL + $20.7 platform Seattle Genetics Inc. October 26, 2018 H.C. WAINWRIGHT & CO. EQUITY RESEARCH 2+ $3.1 cash). Key risks to achievement of our target price include trial failures, safety issues, regulatory delays, competition, and dilutive financing." (10/26/2018)
- 3. According to Zacks Investment Research, "Seattle Genetics' sole marketed drug, Adcetris, is performing well since its launch. The label expansion in frontline Hodgkin lymphoma, pcALCL, CD30-expressing MF and T-cell lymphoma is encouarging. The FDA approval of Adcetris in combination with chemotherapy for the treatment of stage III or IV classical Hodgkin lymphoma (cHL) will further boost sales. The company’s collaboration with Takeda for the global development and commercialization of Adcetris shows promise. However, its heavy dependence solely on Adcetris for growth has its inherent risks. The recent label expansion of Merck’s Keytruda in the lymphoma indication is likely to increase competition. Though the company has multiple candidates in its pipeline, most are in early stages of development. Meanwhile, the company’s shares have outperformed the industry so far this year." (10/23/2018)
- 4. JPMorgan Chase & Co. analysts commented, "With SGEN’s recent strength (up ~50% over the last 3 mos), we’ve been asked frequently – what would we need to see from Adcetris to maintain this momentum? In our view, this question should be more than adequately answered following a big beat this quarter with Adcetris sales coming in at $122.4M vs guidance of $105-110M and consensus of $107M. Additionally, management provided 3Q guidance of $130-135M vs cons of $115M. Coupled with continued pipeline progress (completion of enrollment in the pivotal cohort of EV-201 and first patient dosed in innovaTV 204/207, as previously disclosed), as well as narrowing of guidance for E-2 (now early 4Q18) we see this as another productive quarter on many fronts." (7/27/2018)
Has Seattle Genetics been receiving favorable news coverage?
Media coverage about SGEN stock has trended somewhat negative on Wednesday, InfoTrie Sentiment reports. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Seattle Genetics earned a news sentiment score of -1.9 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future.
Who are some of Seattle Genetics' key competitors?
Some companies that are related to Seattle Genetics include Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), BIO-TECHNE (TECH), Ablynx (ABLYF), Allogene Therapeutics (ALLO), argenx (ARGX), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP) and Denali Therapeutics (DNLI).
Who are Seattle Genetics' key executives?
Seattle Genetics' management team includes the folowing people:
- Dr. Clay B. Siegall, Co-Founder, Chairman, Pres & CEO (Age 57)
- Mr. Todd E. Simpson, Chief Financial Officer (Age 57)
- Dr. Vaughn B. Himes, Chief Technology Officer (Age 57)
- Ms. Jean I. Liu, Gen. Counsel, Exec. VP of Legal Affairs & Corp. Sec. (Age 50)
- Dr. Jonathan G. Drachman, Strategic Advisor for Innovation (Age 56)
Who are Seattle Genetics' major shareholders?
Seattle Genetics' stock is owned by many different of institutional and retail investors. Top institutional shareholders include Primecap Management Co. CA (9.03%), Baillie Gifford & Co. (8.42%), Capital International Investors (5.88%), BlackRock Inc. (5.65%), First Trust Advisors LP (1.12%) and Manning & Napier Group LLC (0.94%). Company insiders that own Seattle Genetics stock include Bros Advisors Lp Baker, Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Institutional Ownership Trends for Seattle Genetics.
Which major investors are selling Seattle Genetics stock?
SGEN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Baillie Gifford & Co., Wasatch Advisors Inc., FMR LLC, Manning & Napier Group LLC, Mitsubishi UFJ Trust & Banking Corp, Pictet Asset Management Ltd. and TIAA CREF Investment Management LLC. Company insiders that have sold Seattle Genetics company stock in the last year include Clay B Siegall, Darren S Cline, Eric Dobmeier, Jonathan G Drachman, Marc E Lippman, Todd E Simpson and Vaughn B Himes. View Insider Buying and Selling for Seattle Genetics.
Which major investors are buying Seattle Genetics stock?
SGEN stock was acquired by a variety of institutional investors in the last quarter, including Capital International Investors, First Trust Advisors LP, Morgan Stanley, BlackRock Inc., Fosun International Ltd, Archon Partners LLC, Dimensional Fund Advisors LP and Castleark Management LLC. View Insider Buying and Selling for Seattle Genetics.
How do I buy shares of Seattle Genetics?
Shares of SGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Seattle Genetics' stock price today?
One share of SGEN stock can currently be purchased for approximately $56.19.
How big of a company is Seattle Genetics?
Seattle Genetics has a market capitalization of $9.14 billion and generates $482.25 million in revenue each year. The biotechnology company earns $-125,530,000.00 in net income (profit) each year or ($0.88) on an earnings per share basis. Seattle Genetics employs 1,100 workers across the globe.
What is Seattle Genetics' official website?
How can I contact Seattle Genetics?
Seattle Genetics' mailing address is 21823 30TH DRIVE SE SUITE, BOTHELL WA, 98021. The biotechnology company can be reached via phone at 425-527-4000 or via email at [email protected]
MarketBeat Community Rating for Seattle Genetics (NASDAQ SGEN)
MarketBeat's community ratings are surveys of what our community members think about Seattle Genetics and other stocks. Vote "Outperform" if you believe SGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
